MTHFR, folic acid or methylfolate — what matters?

If you've had an MTHFR result, or been told you need "methylated" folate, this is the full picture. If not, the short answer above is all you need.

What you'll hear, and what the research shows

What CC, CT and TT mean

You have two copies of every gene, one from each parent. The common MTHFR variation is called C677T. CC means no copies, CT one, TT two. TT slows the enzyme the most and is linked to slightly lower folate and higher homocysteine, especially when folate intake is low. It's very common: as the CDC puts it, more people in the United States carry at least one copy than don't. A variation that common is a normal human difference, not a defect.

If MTHFR has come up for you

The useful number is your homocysteine, a simple blood test — not the gene. Labs such as Cleveland Clinic have stopped MTHFR genotyping for exactly this reason: the homocysteine level is what guides care, whatever the genotype. And if you're TT, ask about riboflavin (vitamin B2): the variant loosens the enzyme's grip on a B2-based helper molecule, and B2 has trial evidence specifically in people with two copies.

The research behind each claim

Why "can't process folic acid" is wrong. Folic acid is converted by an enzyme called DHFR. MTHFR acts one step later, on a conversion that folate from food has to go through too — so a variant affects spinach exactly as it affects a fortified cereal. People with two copies run about 16% lower blood folate at the same intake: a real difference, not an inability. The CDC: "People with an MTHFR gene variant can process all types of folate, including folic acid."

Blood folate. In a 24-week randomized trial of 136 people, red blood cell folate rose more on methylfolate than on folic acid. A 2026 pregnancy trial found the two equivalent in the mother's blood, the placenta and cord blood.

Unconverted folic acid. Human liver converts folic acid remarkably slowly — under 2% of the rate in rats, with about fivefold differences between people — so some circulates unconverted. The 2026 trial found it detectable in 7% of women on methylfolate versus 31% on folic acid, and less of it in the placenta. That trial was funded by Ritual, which makes methylfolate prenatals, and four of its authors work there. It was pre-registered and double-blind and we think it's good work, but the two prenatals also differed in folate dose and other nutrients.

Does unconverted folic acid matter? This is the hinge, and it's unresolved. A 2026 systematic review of 61 studies found the health associations "inconsistent, confounded by total folate, and unreplicated." Lowering a marker is only worth something if the marker matters.

Is it worse with MTHFR? There's no mechanism for it: unconverted folic acid builds up because DHFR is slow, and DHFR isn't the enzyme MTHFR variants affect. The 2026 trial genotyped its participants and found no difference by genotype at any point. If unconverted folic acid turns out to matter, it matters for everyone — the case for methylfolate is real, and it doesn't rest on MTHFR.

Recurrent miscarriage. The one trial that tested this directly randomized 220 women with three or more unexplained losses, all genotyped, to methylfolate or folic acid before conception through 20 weeks. Methylfolate raised blood folate more, but miscarriage rates and homocysteine lowering were no different.

Neural tube defects. No study has ever tested methylfolate against this outcome. The 2026 trial started at 12 to 16 weeks — the neural tube closes around day 21 to 28.

Testing. No major guideline body recommends MTHFR genotype testing. For people who already have a result, the American College of Medical Genetics notes that carriers with normal homocysteine can be reassured about recurrent loss risk.